Photoimmunotherapy targeting prostate-specific membrane antigen: Are antibody fragments as effective as antibodies?

Journal of Nuclear Medicine

Volumn 56, Issue 1, 2015, Pages 140-144

  Watanabe, Rira ^a   Hanaoka, Hirofumi ^a   Sato, Kazuhide ^a   Nagaya, Tadanobu ^a   Harada, Toshiko ^a   Mitsunaga, Makoto ^a   Kim, Insook ^b   Paik, Chang H ^c   Wu, Anna M ^d   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabody; Minibody; Monoclonal antibody; Pharmacokinetics; Photoimmunotherapy; Prostate specific membrane antigen

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IODINE 125; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN DIABODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN MINIBODY; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; IMMUNOGLOBULIN FRAGMENT; INDOLE DERIVATIVE; MEMBRANE ANTIGEN; PHTHALOCYANINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PHOTOIMMUNOTHERAPY; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTOTHERAPY; RADIOIODINATION; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; INFRARED RADIATION; MALE; NECROSIS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION RESPONSE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; INDOLES; INFRARED RAYS; MALE; MICE; NECROSIS; PHOTOSENSITIZING AGENTS; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84920398451     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.149526     Document Type: Article

References (12)

1. Waldmann TA, Morris JC. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv Immunol. 2006; 90: 83-131.
2. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010; 14: 529-537.
3. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6: 559-565.
4. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011; 3: 349-370.
5. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011; 17: 1685-1691.
6. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005; 23: 1137-1146.
7. Sano K, Mitsunaga M, Nakajima T, Choyke PL, Kobayashi H. In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores. Breast Cancer Res. 2012; 14: R61.
8. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
9. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem. 2012; 23: 604-609.
10. Nakajima T, Sano K, Choyke PL, Kobayashi H. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics. 2013; 3: 357-365.
11. Sano K, Nakajima T, Choyke PL, Kobayashi H. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano. 2013; 7: 717-724.
12. 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin. J Nucl Med. 2000; 41: 755-762.